<DOC>
	<DOC>NCT02147158</DOC>
	<brief_summary>This study will evaluate the superiority of ulipristal acetate vs. placebo for the treatment of bleeding associated with uterine fibroids</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Intermittent Ulipristal Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<criteria>Cyclic abnormal uterine bleeding (heavy or prolonged). Menstrual blood loss (MBL) of â‰¥ 80 mL in the first 8 days of menses. Minimum of one discrete leiomyoma observable by transvaginal ultrasound. Evidence of malignancy or atypical or nonatypical hyperplasia on endometrial biopsy.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>